Heron Therapeutics, Inc.
HRTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.15 | -1.14 | -0.09 |
| FCF Yield | 0.62% | -3.47% | -2.66% | -5.30% |
| EV / EBITDA | -22.32 | -466.91 | 133.78 | 44.23 |
| Quality | ||||
| ROIC | -2.56% | -1.09% | 2.11% | 2.88% |
| Gross Margin | 59.74% | 73.50% | 78.26% | 74.92% |
| Cash Conversion Ratio | -0.08 | 4.56 | -3.37 | -3.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.08% | 8.26% | 9.27% | 10.25% |
| Free Cash Flow Growth | 112.02% | -23.35% | 27.69% | -522.38% |
| Safety | ||||
| Net Debt / EBITDA | -6.97 | -156.17 | 42.64 | 17.40 |
| Interest Coverage | -1.41 | 0.00 | 6.31 | 0.94 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.14 | 0.15 | 0.19 |
| Cash Conversion Cycle | 530.24 | 749.69 | 656.78 | 538.83 |